Norway· NO-ID_4EF03E09-1CE3-4AC1-95C2-A12D29FA3D8C
Bekemv
A eculizumab product containing eculizumab, registered in Norway by Amgen Technology Ireland. The same ATC class is registered in 13 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Eculizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AJ01 (eculizumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Eculizumab · ATC L04AJ01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Eculizumab
- Manufacturer
- Amgen Technology Ireland
- Country
- Norway (NO)
- ATC code
- L04AJ01
- ATC class
- Eculizumab
- Defined daily dose
- 64 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- October 2, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_4EF03E09-1CE3-4AC1-95C2-A12D29FA3D8C
- no_varenummer4071881 x 30NOK 50426.7
- gtin8715131025793
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for eculizumab.
Graded by severity as the source publishes them — 2 minor. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Eculizumab · interactions on record
2 records
Same medicine, other countries
Eculizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumBekemv 300 mgAmgen Europe
- CzechiaBEKEMVAmgen Europe B.V., Breda
- FinlandBEKEMVAmgen Europe B.V.
- IrelandBEKEMV 300 mg Concentrate for solution for infusionAmgen Technology (Ireland) Unlimited Company
- IcelandBekemvAmgen Technology (Ireland) UC*
- PolandBekemvAmgen Technology (Ireland) UC
- SwedenBEKEMV 300 mg Koncentrat till infusionsvätska, lösningAmgen Europe B.V.
- United StatesBKEMVAmgen Inc
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Bekemv, Soliris
- Liechtenstein · Soliris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/62044b5a-b952-4c02-a873-cd6e94ba1c32 GET /v1/drugs/62044b5a-b952-4c02-a873-cd6e94ba1c32?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Konsentrat til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Ekulizumab",
"merkevare_id": "ID_4EF03E09-1CE3-4AC1-95C2-A12D29FA3D8C",
"name_form_strength": "Bekemv kons til inf oppl 300 mg",
"prescription_group": "C"
}See everything about eculizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.